Rod and Cone Dark Adaptation in Congenital Aniridia and Its Association With Retinal Structure.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
03 04 2023
Historique:
medline: 19 4 2023
entrez: 17 4 2023
pubmed: 18 4 2023
Statut: ppublish

Résumé

To characterize the association between dark-adapted rod and cone sensitivity and retinal structure in PAX6-related aniridia. Dark-adaptation curves were measured after a 5-minute exposure to bright light with red (625 nm) and green (527 nm) 2° circular light stimuli presented at ≈20° temporal retinal eccentricity in 27 participants with aniridia (nine males; 11-66 years old) and 38 age-matched healthy controls. A two-stage exponential model was fitted to each participant's responses to determine their cone and rod thresholds over time. The thicknesses of macular inner and outer retinal layers were obtained from optical coherence tomography images in 20 patients with aniridia and the 38 healthy controls. Aniridia-associated keratopathy (AAK) grade (0-3) and lens opacities were quantified by clinical examination of the anterior segment. The rod-cone break time was similar between patients with aniridia and healthy controls. Dark-adapted cone and the rod thresholds were higher in aniridia compared with healthy controls. In aniridia, foveal outer retinal layer thickness correlated with both final cone and rod thresholds. A multiple regression model indicated that foveal outer retinal layer thickness and age were the main explanatory variables to predict both final cone and rod thresholds in aniridia when the AAK grade was 2 or less. The results show that both rod- and cone-related functions are affected in PAX6-related aniridia and suggest that retinal anatomical and physiological changes extend beyond the area commonly studied in this condition: the central macula.

Identifiants

pubmed: 37067366
pii: 2785540
doi: 10.1167/iovs.64.4.18
pmc: PMC10120381
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18

Références

Prog Retin Eye Res. 2022 Oct 21;:101133
pubmed: 36280537
Can J Ophthalmol. 2017 Dec;52(6):570-577
pubmed: 29217025
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4537-45
pubmed: 26200492
Arch Ophthalmol. 1993 Jun;111(6):831-6
pubmed: 8512486
Invest Ophthalmol Vis Sci. 2020 May 11;61(5):14
pubmed: 32396632
Prog Retin Eye Res. 2004 May;23(3):307-80
pubmed: 15177205
Dev Biol. 2017 Dec 1;432(1):140-150
pubmed: 28993200
Am J Ophthalmol. 2012 Nov;154(5):779-789.e2
pubmed: 22898189
Elife. 2017 Jan 31;6:
pubmed: 28139974
Development. 2008 Dec;135(24):4037-4047
pubmed: 19004853
Behav Res Methods Instrum Comput. 1999 Nov;31(4):712-7
pubmed: 10633991
Prog Retin Eye Res. 2012 Sep;31(5):351-76
pubmed: 22561546
PLoS Genet. 2014 May 29;10(5):e1004360
pubmed: 24875170
Cell. 2001 Apr 6;105(1):43-55
pubmed: 11301001
J Clin Med. 2022 Mar 01;11(5):
pubmed: 35268448
Doc Ophthalmol. 2021 Dec;143(3):283-295
pubmed: 34173938
Ophthalmol Retina. 2019 Jun;3(6):523-534
pubmed: 31174676
Prog Retin Eye Res. 2018 Sep;66:49-84
pubmed: 29609042
Am J Ophthalmol. 1979 Apr;87(4):497-502
pubmed: 375739
Eye (Lond). 2016 Aug;30(8):1135-43
pubmed: 27229708
J Comp Neurol. 1990 Feb 22;292(4):497-523
pubmed: 2324310
Surv Ophthalmol. 2018 Jan - Feb;63(1):105-113
pubmed: 28923585
Br J Ophthalmol. 2019 Jan;103(1):119-124
pubmed: 29519880
Am J Ophthalmol. 2012 Nov;154(5):767-778.e2
pubmed: 22935600
Eye (Lond). 2007 Jan;21(1):90-3
pubmed: 16254589
Development. 2014 Mar;141(6):1292-302
pubmed: 24523460
Vis Neurosci. 2012 Jan;29(1):51-60
pubmed: 22310372
Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):2142-2152
pubmed: 29801149
Vision Res. 1999 Nov;39(23):3975-82
pubmed: 10748929
Am J Ophthalmol. 2022 May;237:122-129
pubmed: 34942114
J Comp Neurol. 1990 Oct 1;300(1):5-25
pubmed: 2229487
Eur J Ophthalmol. 2020 Jan;30(1):58-65
pubmed: 30556423
Invest Ophthalmol Vis Sci. 2019 Jul 1;60(8):2848-2859
pubmed: 31260035
J Physiol. 1961 Apr;156:166-78
pubmed: 13744792
eNeuro. 2021 Feb 24;8(1):
pubmed: 33188005
Exp Eye Res. 2018 Aug;173:138-147
pubmed: 29775563
Am J Ophthalmol. 1998 Aug;126(2):211-8
pubmed: 9727515
Yan Ke Xue Bao. 1991 Sep;7(3):151-2, 119
pubmed: 1842369
Optom Vis Sci. 1995 Dec;72(12):907-10
pubmed: 8749339

Auteurs

Hilde R Pedersen (HR)

National Centre for Optics, Vision and Eye Care, Faculty of Health and Social Sciences, University of South-Eastern Norway, Kongsberg, Norway.

Stuart J Gilson (SJ)

National Centre for Optics, Vision and Eye Care, Faculty of Health and Social Sciences, University of South-Eastern Norway, Kongsberg, Norway.

Erlend C S Landsend (ECS)

Department of Ophthalmology, Oslo University Hospital, Oslo, Norway.

Øygunn A Utheim (ØA)

Department of Ophthalmology, Oslo University Hospital, Oslo, Norway.

Tor P Utheim (TP)

National Centre for Optics, Vision and Eye Care, Faculty of Health and Social Sciences, University of South-Eastern Norway, Kongsberg, Norway.
Department of Ophthalmology, Oslo University Hospital, Oslo, Norway.

Rigmor C Baraas (RC)

National Centre for Optics, Vision and Eye Care, Faculty of Health and Social Sciences, University of South-Eastern Norway, Kongsberg, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH